Insmed | INSM - Pre Tax Profit

Stock Price
134.66
Daily Change
-1.67 -1.23%
Monthly
-17.10%
Yearly
86.25%
Q2 Forecast
132.28

Insmed reported $-326.93M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -326.93M 41.77M Dec/2025
Novartis USD 5.17B 637M Sep/2025
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025